NEW YORK (GenomeWeb News) – The US Federal Trade Commission announced on Tuesday it has reached an agreement with GeneLink and its former subsidiary foru International to settle charges of deceptive advertising claims made by the companies about their personalized nutritional supplements.

The settlement, which is not yet final, would also resolve allegations that GeneLink and foru engaged in "lax information security practices," the FTC said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.